Capstone Therapeutics Corp. 2014 Q1 10-Q Summary
Reporting period: Three months ended March 31, 2014. The filing identifies the registrant as Capstone Therapeutics Corp., a development-stage biotechnology company; the request metadata refers to Capstone Holding Corp. The company had 40,885,411 common shares outstanding as of April 30, 2014.
Business Context
The company develops peptide and other molecular therapeutics for underserved medical conditions. Its principal active program is AEM-28, being developed through the 60%-owned LipimetiX Development LLC joint venture for severe refractory hypercholesterolemia and homozygous familial hypercholesterolemia. The company has ceased clinical development of AZX100 for dermal scarring, continues limited fibrosis-related preclinical work, and is seeking licensing or development partners. It operates primarily under a virtual operating model.
Key Financial Metrics
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Revenue | No revenue reported | No revenue reported | Not applicable |
| General and administrative expense | $452,000 | $433,000 | Up $19,000 |
| Research and development expense | $630,000 | $912,000 | Down $282,000 |
| Total operating expenses | $1.082 million | $1.345 million | Down $263,000 |
| Interest and other income, net | $60,000 | $157,000 | Down $97,000 |
| Net loss | $1.022 million | $1.188 million | Improved $166,000 |
| Net loss per share | $0.02 | $0.02 | No disclosed change |
| Cash flow from operations | $(768,000) | $(1.008) million | Use decreased $240,000 |
| Cash and cash equivalents at period-end | $5.490 million | $9.201 million | Down $3.711 million |
At March 31, 2014, total assets were $6.511 million, total current liabilities were $288,000, and stockholders’ equity was $6.223 million. The company reported no debt. Of its cash balance, $1.716 million was held by LipimetiX and reserved for joint-venture use, leaving it unavailable for general corporate purposes. The accumulated development-stage deficit was $155.278 million.
Material Changes Versus the Prior Comparable Period
- Research and development expense declined primarily because LipimetiX operating expenses included in the consolidated results fell to approximately $418,000 from $831,000.
- General and administrative expense was broadly stable.
- Net loss attributable to company stockholders improved to $1.022 million from $995,000 in the prior-year presentation; consolidated net loss was $1.022 million versus $1.188 million. The difference reflects the prior-year allocation of $193,000 of loss to the noncontrolling interest.
- Operating cash use improved, but period-end cash declined from $6.258 million at December 31, 2013 to $5.490 million at March 31, 2014.
- Accounts payable increased to $253,000 from $88,000 and accrued liabilities increased to $35,000 from $12,000.
Guidance, Outlook, Risks, and Unusual Items
- The LipimetiX AEM-28 Phase 1a trial commenced in Australia in April 2014. The initial development plan, including Phase 1a and Phase 1b/2a studies, was expected to be completed in the fourth quarter of 2014, subject to regulatory and development results.
- Management estimated 2014 cash expenditures of approximately $4.0 million, including approximately $2.5 million for LipimetiX. This estimate excludes potentially significant and currently unquantifiable qui tam litigation costs.
- Management stated that cash and short-term investments were expected to fund projected requirements for the next twelve months, but substantial additional capital would be required to complete clinical development and obtain regulatory approvals. Future financing could dilute existing stockholders or be unavailable on acceptable terms.
- The company is defending a qui tam False Claims Act and related state and local claims concerning its former bone-device business. The government declined to intervene, no trial date had been set, and discovery was open. Management believed a material loss was not reasonably possible based on available information, but noted that an adverse outcome could materially impair liquidity, financial position, operations, and the ability to continue the business.
- The company reduced its workforce from eighteen employees to two and continued transitioning toward a virtual operating model.
- Outstanding options and warrants covered 3,222,835 shares, with exercise prices ranging from $0.16 to $6.39 per share; 302,895 potentially dilutive shares were excluded from diluted loss-per-share calculations as anti-dilutive.
- The filing reported no material changes to previously disclosed risk factors and concluded that disclosure controls and procedures were effective.
Investor Verification Items
- Confirm the registrant’s legal name and ticker, because the filing is for Capstone Therapeutics Corp., not Capstone Holding Corp.
- Verify the unrestricted cash available to the parent after excluding the $1.716 million reserved for LipimetiX.
- Track LipimetiX’s clinical progress, funding needs, regulatory approvals, and the company’s potential obligation to absorb further joint-venture losses.
- Review the status and potential financial exposure of the qui tam litigation, including legal costs and any settlement or damages risk.
- Assess the company’s ability to fund operations and clinical development without significant equity dilution, debt, licensing transactions, or additional partners.
- Evaluate AZX100 partnering prospects and the likelihood that the company’s limited virtual operating model can preserve cash while advancing its pipeline.